Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
暂无分享,去创建一个
Li Ding | William Pao | Elaine R Mardis | Marc Ladanyi | R. Wilson | E. Mardis | L. Ding | M. McLellan | M. Ladanyi | V. Rusch | Roman K. Thomas | W. Pao | D. Solit | J. Marks | R. Levine | K. Michel | Y. Kasai | Y. Gong | D. Chitale | Richard K Wilson | Kathrin Michel | Yixuan Gong | David Solit | Michael D McLellan | Ross Levine | Valerie W Rusch | Roman K Thomas | Dhananjay Chitale | Yumi Kasai | Jenifer L Marks | Ben Golas | B. Golas | R. Wilson
[1] H. Lodish,et al. Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F* , 2008, Journal of Biological Chemistry.
[2] Y. Makita,et al. Leukemia in Cardio-facio-cutaneous (CFC) Syndrome: A Patient With a Germline Mutation in BRAF Proto-oncogene , 2007, Journal of pediatric hematology/oncology.
[3] N. Ahn,et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.
[4] F. McCormick,et al. Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy , 2007, PloS one.
[5] G. Daley,et al. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[6] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[7] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[8] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[9] H. Sasaki,et al. PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.
[10] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[11] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[12] R. Wilson,et al. Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4 , 2007, PloS one.
[13] C. Crews,et al. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. , 1992, Science.
[14] Pablo Rodriguez-Viciana,et al. Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.
[15] J. Stone,et al. RAS signalling is abnormal in a c-raf1 MEK1 double mutant , 1995, Molecular and cellular biology.
[16] A. Chudley,et al. Rhabdomyosarcoma in a patient with Cardio-Facio-Cutaneous syndrome. , 2000, Journal of pediatric hematology/oncology.
[17] K. Gripp,et al. Hepatoblastoma and heart transplantation in a patient with cardio‐facio‐cutaneous syndrome , 2007, American journal of medical genetics. Part A.
[18] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[19] David L. Brautigan,et al. Raf-1 activates MAP kinase-kinase , 1992, Nature.
[20] D. Horn,et al. Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome , 2007, Clinical genetics.